Kornimate/medical-research-clean huggingface dataset:
quantitative c-reactive protein for differentiating tuberculous and malignant pleural effusion: a cross-sectional study

Conditions: Pleural Effusion; Malignant Pleural Effusions; Tuberculous Pleural Effusion

Summary: the goal of this observational study is to evaluate the role of pleural fluid quantitative c-reactive protein (q-crp) levels in distinguishing between tuberculous and malignant pleural effusion in adult patients with lymphocytic exudative pleural effusion. the main questions it aims to answer are: is pleural fluid q-crp significantly higher in tuberculous pleural effusion compared to malignant pleural effusion? what is the optimal cutoff value of pleural fluid q-crp to differentiate between these conditions? participants will: undergo diagnostic procedures such as pleural fluid analysis, including ada and cytology. provide pleural fluid samples for q-crp measurement. have additional diagnostic imaging or biopsies if clinically indicated. researchers will compare q-crp levels between the tuberculous pleural effusion group and the malignant pleural effusion group to determine its diagnostic accuracy, including sensitivity, specificity, and predictive value.


Eligibility criteria:
inclusion criteria: * adults aged 18 years and older. * patients presenting with lymphocytic exudative pleural effusion confirmed by light's criteria. * lymphocyte predominance in pleural fluid (≥ 50% of differential count). exclusion criteria: * patients who refuse to provide consent for study participation. * patients requiring biopsy under general anesthesia but found unfit for the procedure. * non-tuberculous and non-malignant lymphocytic exudative pleural effusions identified during diagnostic evaluation.
milk and growth in children (magic) born very preterm: a randomized trial

Conditions: Prematurity

Summary: the goal of this multi-center randomized, parallel group trial is to determine the effect of human milk diets ranging between 180 and 200 ml/kg/day on the body composition outcomes of moderately preterm infants born between 27 and 31 weeks of gestation.

participants will be randomized once they reach 120 ml/kg/day. clinicians will be able to increase feeds each day as they see fit, until the patient reaches the target goal of 140-160 ml/kg/day or 180-200 ml/kg/day. they will then maintain this volume until 34 weeks postmenstrual age. researchers will compare these two targets to see if higher feeding volumes prevent faltering growth without causing adverse metabolic outcomes. participants will: * have a feeding volume of 180-200 ml/kg/day or a volume of 140-160 ml/kg/day until 34 weeks corrected age * have four body composition assessments with a bioelectrical impedance analyzer throughout study period * have four stool samples collected throughout study period * have four maternal breastmilk samples collected and analyzed throughout the study period * have one blood sample collected at 36 weeks corrected age * have the option to participate in a follow-up survey completed by parents at 2-3 years of age

Eligibility criteria:
inclusion criteria: * gestational age between 27 0/7 and 31 6/7 weeks * birthweight of 1500 grams or less * human milk feeding during the first 14 days after birth * full enteral feeding (120ml/kg/day or more) within the first 14 days after birth exclusion criteria: * necrotizing enterocolitis stage 2 or greater * spontaneous intestinal perforation * major congenital/chromosomal anomalies * terminal illness requiring limited or withheld support * intention to restrict fluid intake after the first 14 postnatal days due to the presence of a symptomatic patent ductus arteriosus (pda) * any formula feeding within the first 14 days after birth
longitudinal registry of endovascular thoracoabdominal aneurysms

Conditions: Aneurysm; Aortic Aneurysm

Summary: the purpose of this study is to evaluate the long-term safety and performance of complex endovascular aneurysm repair by inclusion in a longitudinal registry

this is a global, multicenter, prospective, observational, non-randomized, single-arm, open clinical study will evaluate the long term (i.e. \>5 years) safety and efficacy of complex endovascular repair this study will enroll all patients treated with fenestrated and branched devices in europe and canada that follow all inclusion criteria and none of the exclusion criteria. the total duration of the study will be of approximately 7 years.

Eligibility criteria:
inclusion criteria: * patient eligibility for enrolment shall be based on known information at the time of the procedure. information obtained at a later date may contradict these criteria, but this will not be considered a deviation of the study plan. inclusion criteria a patient is deemed suitable for inclusion in the study if the patient meets both of the following criteria: 1. patient requires endovascular repair of a thoracic, thoraco-abdominal or abdominal aortic or aorto-iliac aneurysm having morphology suitable for endovascular repair with complex endograft. 2. patients (or their legal representative for minor patients) who do not object to (oral non-objection declaration, and signed consent form) collection and transmission of his/her data. exclusion criteria: * patients are excluded from enrolment into the study if any of the following are true: 1. patients whose imaging follow-up is impossible, i.e. patients who are not able to send their follow up ct scans or duplex us
study of navtemadlin as maintenance therapy in tp53wt advanced or recurrent endometrial cancer

Conditions: Endometrial Cancer

Summary: this study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (ec) who have achieved complete response or partial response on chemotherapy. the study will be conducted in 2 parts. part 1 will evaluate safety and efficacy of two different doses of navtemadlin alongside an observational control arm to determine the phase 3 navtemadlin dose. part 2 will evaluate the efficacy and safety of navtemadlin phase 3 dose compared to placebo.


Eligibility criteria:
inclusion criteria: * ecog 0-1 * histologically or cytologically confirmed diagnosis of endometrial cancer documented as tp53wt * subjects with advanced or recurrent disease must have completed a single line of up to 6 cycles of taxane-platinum based chemo and achieved a cr or pr per recist v1.1 * adequate hematologic, hepatic and renal function (within 14 days) exclusion criteria: * has any sarcomas or small-cell carcinomas with neuroendocrine differentiation * prior immune therapy, cytokine therapy, or any investigational therapy (within 28 days) * indwelling surgical drains * grade 2 or higher qtc prolongation * history of major organ transplant * history of bleeding diathesis; major hemorrhage or intracranial hemorrhage (within 24 weeks)

Keywords: navtemadlin
a study to evaluate the efficacy and safety of shr0302 in patients with non-radiographic axial spondyloarthritis

Conditions: Non-radiographic Axial Spondyloarthritis

Summary: this study is to evaluate the efficacy and safety of shr0302 in subjects with active non-radiographic axial spondyloarthritis.


Eligibility criteria:
inclusion criteria: 1. provide signed informed consent. 2. bmi ≥18 kg/m2. 3. participant has the clinical diagnosis of nr-axspa fulfilling the 2009 asas classification criteria for axspa but not meeting the radiologic criterion of the modified new york criteria for as and have objective signs of active inflammation on magnetic resonance imaging (mri) or based on high sensitivity c-reactive protein (crp). 4. participant must have baseline disease activity as defined by having a bath ankylosing spondylitis disease activity index (basdai) score \>= 4 and a patient's assessment of total back pain score \>= 4 based on a 0 - 10 numeric rating scale (nrs) at the screening and baseline visits. 5. participant has had an inadequate response to at least two nonsteroidal anti-inflammatory drugs (nsaids) over an at least 4-week period in total at maximum recommended or tolerated doses, or participant has an intolerance to or contraindication for nsaids as defined by the investigator. 6. if subjects are taking permitted csdmards or low-dose corticosteroid orally at baseline, the stable doses should have lasted for more than 4 weeks already. exclusion criteria: 1. pregnant women or refuse to receive contraception during the study. 2. lab abnormality within 4 weeks of randomization as follows: wbc count \<3.0×10\^9/l；neutrophil count\<1.5×10\^9/l;hemoglobin level\<90.0 g/l ; platelet count \<100×10\^9/l; ast or alt levels greater than the 1.5 times the upper limit of normal; hbsag or hcv or hiv antibody positivity. 3. history of other autoimmune diseases ; history of cancer or infection including tuberculosis and hepatitis; history of important cardiovascular events or thrombotic diseases.
systems-oriented school healthy weight promotion based on nasa mission x campaign

Conditions: Pediatric Obesity

Summary: this study assessed the effect of the national aeronautics and space administration's (nasa's) mission x (mx) program on children's knowledge, attitude, and practice of healthy eating and active living (heal) and weight status in rural elementary schools in taiwan.


Eligibility criteria:
inclusion criteria: * the thirteen public elementary schools in tamsui, sanzhi and shimen districts, new taipei city, taiwan, were the target population. schools that were in distance within 30 minutes by car from mackay medical college were approached. eight schools agreed to participate. all 3rd and 4th graders of the participating schools were invited to the evaluation program. exclusion criteria: -
rsa study of sirius stem and exceed cup

Conditions: Osteoarthritis

Summary: the purpose of this study is to evaluate the efficacy and safety of the sirius cemented stem used in conjunction with the exceed abt cemented acetabular cup, either with e1 or arcom polyethylene, and optipac/optivac bone cement mixing systems.

this is a comparative, prospective randomized radiostereometry (rsa) study, lead on 48 patients in a single site. all 48 patients will be pooled in a single group for the evaluation of the primary criterion for evaluation, but randomized into four groups for the evaluation of the secondary criteria for evaluation the objectives of the study are to: 1. demonstrate a comparable migration pattern as is described in published literature on other double tapered polished cemented stems 2. measure wear pattern in the cup made of vitamin-e doped polyethylene or conventional arcom polyethylene 2)demonstrate non-inferiority of optipac vs. optivac cement mixing systems on the stem side 3)evaluate the clinical outcome and survivorship of the implant

Eligibility criteria:
inclusion criteria: 1. patients who are eligible for cemented total hip arthroplasty 2. patients diagnosed with primary osteoarthritis 3. patients who are fit for elective surgery (asa i - iii) 4. patients with a bmi between 16 and 40 5. patients who are skeletally mature 6. patients aged over 18 at the time of surgery 7. patients willing to return for follow-up evaluations 8. patients who have the ability to follow instructions 9. patients with sufficient bone stock and quality exclusion criteria: 1. female patients who are pregnant or planning pregnancy during the course of the study (no use of adequate birth control) 2. patients with diagnosed active infection 3. patients with marked bone loss which could preclude or compromise adequate fixation of the device 4. patients with parkinson disease 5. patients using immunosuppressive drugs 6. patients with an immunosuppressive disease 7. patients with bmi \<16 8. patient with bmi \>40 9. patients who are unfit for surgery (asa iv - v) 10. patients with acetabular or femoral osteotomy 11. patients who had a tha on the contralateral side within last 6 months 12. patients belonging to the vulnerable population: children, patients with mental

Keywords: total hip replacement
efficacy of radial keratotomy in the optical rehabilitation of mild to moderate keratoconus cases

Conditions: Radial Keratotomy in Keratoconus Cases

Summary: keratoconus is a progressive ectatic disorder that steepens the cornea resulting in a conical shape. radial keratotomy can provide an optical rehabilitation by its flattening effect. it can also halt the progression of disease owing to fibrotic activation in perpendicular corneal incisions.


Eligibility criteria:
inclusion criteria: * keratoconus with a central corneal thickness (cct) over 400µm, * poor corrected visual acuity (≤0.4 at snellen visual acuity charts), * contact lens intolerance exclusion criteria: * apical scarring, * ocular or systemic problem other than keratoconus

Keywords: radial keratotomy; keratoconus; optical rehabilitation
plasma neutrophil gelatinase associated lipocalin levels during emergency management of rhabdomyolysis

Conditions: Rhabdomyolysis; Acute Kidney Failure

Summary: this research project consists of a prospective diagnostic study conducted on patients with clinical suspicion of rhabdomyolysis admitted to the emergency rooms of the university hospitals of nimes, montpellier, paris, nice and toulon inter army hospital. the main objective of this study is to determine whether the plasma level of neutrophil gelatinase associated lipocalin (ngal) may be retained as a predictor of acute renal failure (arf) occurring within 48 hours after admission for rhabdomyolysis.

the secondary objectives of this are: * to study plasma ngal levels on admission to the emergency ward as a marker of morbidity and mortality by considering the following factors: duration of hospitalization, need for extracorporeal blood purification, icu admission, death. * to study the delay between the onset of the proposed cause of rhabdomyolysis and treatment initiation * to study the delay between treatment initiation and the occurrence of arf.

Eligibility criteria:
inclusion criteria: * the patient must have given his/her informed and signed consent * the patient must be insured or beneficiary of a health insurance plan * patient hospitalized with creatine phospho-kinase \> 1000 ui/l exclusion criteria: * the patient is participating in another study * the patient is in an exclusion period determined by a previous study * the patient is under judicial protection, under tutorship or curatorship * the patient refuses to sign the consent * it is impossible to correctly inform the patient * the patient is pregnant, parturient, or breastfeeding * chronic renal insufficiency with dialysis * the patient has an acute coronary syndrome * nephrotoxic medications within 72 hours prior to admission * need for a procedure involving the injection of iodine * patient in shock * occurrence of acute renal failure can be explained by a cause other than rhabdomyolysis.

Keywords: neutrophil gelatinase associated lipocalin predicting acute kidney failure emergency room
music therapy on nausea and pain for autologous stem cell

Conditions: Multiple Myeloma; Non-Hodgkin Lymphoma; Hodgkin Lymphoma

Summary: autologous stem cell transplant (asct) is an important therapy for patients with multiple myeloma, non-hodgkin's lymphoma, and hodgkin's lymphoma. it has been shown to improve progression free survival and overall survival. however, it is a challenging treatment process both physically and psychologically. it is a procedure with many side effects that can be uncomfortable, painful, and at times, difficult to endure. complementary therapies, such as music therapy, have potential to be an important adjunct in palliation of symptoms in patients undergoing chemotherapy.

patients randomized to receive music therapy will receive 2 sessions of live music therapy, at least 48 hours apart, from a music therapist-board certified (mt-bc, certified through the certification board for music therapists) in their room. this will occur between days -1 and +5, with the first music therapy session being as close to day +1 as possible and the second session being at least 48 hours later (but no more than 96 hours later). those patients randomized to standard therapy (no music therapy) are allowed to listen to music; however they will not receive interactive music therapy from a certified therapist. following day +7, music therapy will be offered to all patients who are interested in participating. no narcotic or anti-emetic therapy will be administered for at least 2 hours prior to music therapy sessions or to assessments. patients will rate nausea and pain at the beginning and end of the first music therapy session on a validated visual analog scale.12-14 the scale will be 10cm with the least nausea or pain at point 0 and the greatest nausea or pain at point 10. patients will be asked to rate their nausea and pain on day +5 and day +7.

Eligibility criteria:
inclusion criteria: * be older than 18 years of age * have a diagnosis of multiple myeloma, non-hodgkin, or hodgkin lymphoma * be undergoing asct (autologous stem cell transplantation) exclusion criteria: * have had previous asct * have a diagnosis of leukemia * history of prior music therapy

Keywords: autologous stem cell transplantation multiple myeloma non-hodgkin hodgkin lymphoma music therapy nausea pain
safety and tolerance of local heat application in the paralyzed area of patients with complete paraplegia

Conditions: Perfusion; Complications

Summary: preconditioning of regional skin is known to reduce post surgery complications due to increased perfusion and better skin condition. the aim of this study is to prove that local heating through a standardized device in patients with spinal cord injury induces no burnings or other relevant side effects. the investigators expect an increased regional perfusion, temperature and redness.


Eligibility criteria:
inclusion criteria: * men and women * aged from 18 to 65 years * paraplegia th2-th12 * spinal cord injury had occurred \>12 weeks ago exclusion criteria: * infections * fever * diabetes * heart failure stadium iii * renal insufficiency stadium iii. * scars, wounds or other injuries in the area of treatment * skin type v and vi on fitzpatrick scale

Keywords: complete paraplegia
why does aspirin fail in secondary cerebrovascular prevention? a multicenter prospective case - control study

Conditions: Cerebrovascular Disease

Summary: multicenter prospective observational case-control study aimed at characterizing the possible determinants of treatment failure in patients with cerebrovascular disease on secondary prevention with asa, who are hospitalized in internal medicine departments for a recurrent atherothrombotic stroke.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years 2. swallow-test positive 3. patients hospitalized for a first event of athero-thrombotic stroke (control group) 4. patients hospitalized for a recurrence of athero-thrombotic stroke on asa therapy (case group) 5. informed consent exclusion criteria: 1. transient ischemic attack (tia) 2. chronic treatment with non-steroidal anti-inflammatory drugs (if occasional, not within 4 days prior to hospitalization) 3. current treatment with oral or parental anticoagulants at prophylactic or therapeutic doses 4. current treatment with other antiplatelet agents 5. thrombolysis and thrombectomy 6. cardio-embolic stroke centro studi fondazione fadoi page 10 studio fadoi.01.2018 versione n. 2 del 26/09/2019 7. carotid stenosis \>70%, with indication for revascularization 8. current treatment with asa (only for patients in the control group) 9. acute hepatitis, chronic active hepatitis, liver cirrhosis - or alanine aminotransferase level 3 times or more and/or bilirubin level 2 times or more higher than the upper limit of the normal range 10. thrombocytopenia (\<150000 platelets/μl) 11. renal failure (egfr \<30 ml/min) 12. active cancer or disease in complete remission \<1 year, except squamous cell carcinoma and basal-cell carcinoma of the skin at initial stage 13. severe chronic obstructive pulmonary disease (copd) (oxygen therapy) 14. uncontrolled hypertension (systolic bp \>180 mmhg or diastolic bp \>100 mmhg despite antihypertensive treatment) 15. chronic inflammatory bowel disease 16. chronic treatment with corticosteroid drugs (for example prednisone \>5 mg/die or equivalent) 17. pregnancy (in case of child-bearing potential inclusion will be possible in case of negative pregnancy test)
piperacillin sodium and sulbactam sodium for injection (2:1) for treatment of respiratory and urinary tract infection

Conditions: Respiratory Tract Infections; Urinary Tract Infections

Summary: in the proposed study, the investigators plan to evaluate the efficacy and safety of piperacillin sodium and sulbactam sodium for injection (2:1) for the treatment of respiratory and urinary tract acute bacterial infection under the widely used in clinical conditions.

piperacillin sodium and sulbactam sodium for injection (2:1) plays a therapeutic role by the former inhibiting bacterial cell wall synthesis by irreversible competitive inhibition of β-lactamase. the antimicrobial effect of cefotaxime can be enhanced by the two combined. the compound specifically aims to the mechanism of bacterial resistance, extending the life of piperacillin in the treatment-resistant pathogen infections.

Eligibility criteria:
inclusion criteria: 1. patients who qualify for moderate and severe acute respiratory or urinary tract bacterial infection of acute bacterial infections need for systemic antibiotic therapy. 2. age\>18 years old, gender: both 3. women of childbearing age were to be negative pregnancy test and agree to take contraceptive measures during the trial; 4. patients were volunteers and signed informed consent form; 5. patients did not participate in other clinical trials. exclusion criteria: 1. patients were hypersusceptibility to the test drug or other penicillins ,β-lactamase inhibitor 2. pregnant and lactating women 3. patients have severe liver,kidney,cardiovascular,cerebrovascular,endocrine and hematopoietic system of primary diseases and that of immunodeficiency,advanced cancer or mental illness. 4. patients who were complicated by other diseases and thought to affect efficacy evaluations or poor compliance.

Keywords: piperacillin sodium and sulbactam sodium phase iv clinical studies respiratory and urinary tract infections